Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
Identifieur interne : 001D02 ( Main/Exploration ); précédent : 001D01; suivant : 001D03Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
Auteurs : RBID : pubmed:19443590English descriptors
- KwdEn :
- Adult, Aged, Disease Progression, Endocrine Gland Neoplasms (mortality), Endocrine Gland Neoplasms (pathology), Endocrine Gland Neoplasms (radionuclide imaging), Female, Fluorodeoxyglucose F18 (diagnostic use), Humans, Indium Radioisotopes (diagnostic use), Male, Middle Aged, Neoplasm Metastasis, Positron-Emission Tomography (methods), Prospective Studies, Radiopharmaceuticals (diagnostic use), Receptors, Somatostatin (analysis), Somatostatin (analogs & derivatives), Somatostatin (metabolism).
- MESH :
- chemical , analogs & derivatives : Somatostatin.
- chemical , analysis : Receptors, Somatostatin.
- chemical , diagnostic use : Fluorodeoxyglucose F18, Indium Radioisotopes, Radiopharmaceuticals.
- chemical , metabolism : Somatostatin.
- methods : Positron-Emission Tomography.
- mortality : Endocrine Gland Neoplasms.
- pathology : Endocrine Gland Neoplasms.
- radionuclide imaging : Endocrine Gland Neoplasms.
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies.
Abstract
The treatment of metastatic neuroendocrine tumors depends on the aggressiveness of the disease. We wanted to know whether (18)F-FDG PET and somatostatin receptor scintigraphy (SRS) can predict early disease progression and patient survival.
DOI: 10.2967/jnumed.108.057505
PubMed: 19443590
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.</title><author><name sortKey="Garin, Etienne" uniqKey="Garin E">Etienne Garin</name><affiliation wicri:level="1"><nlm:affiliation>UPRESS EA 3890 and Department of Medical Imaging, Centre E. Marquis, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UPRESS EA 3890 and Department of Medical Imaging, Centre E. Marquis, Rennes</wicri:regionArea><placeName><region type="région">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Le Jeune, Florence" uniqKey="Le Jeune F">Florence Le Jeune</name></author><author><name sortKey="Devillers, Anne" uniqKey="Devillers A">Anne Devillers</name></author><author><name sortKey="Cuggia, Marc" uniqKey="Cuggia M">Marc Cuggia</name></author><author><name sortKey="De Lajarte Thirouard, Anne Sophie" uniqKey="De Lajarte Thirouard A">Anne-Sophie de Lajarte-Thirouard</name></author><author><name sortKey="Bouriel, Catherine" uniqKey="Bouriel C">Catherine Bouriel</name></author><author><name sortKey="Boucher, Eveline" uniqKey="Boucher E">Eveline Boucher</name></author><author><name sortKey="Raoul, Jean Luc" uniqKey="Raoul J">Jean-Luc Raoul</name></author></titleStmt><publicationStmt><date when="2009">2009</date><idno type="doi">10.2967/jnumed.108.057505</idno><idno type="RBID">pubmed:19443590</idno><idno type="pmid">19443590</idno><idno type="wicri:Area/Main/Corpus">001E61</idno><idno type="wicri:Area/Main/Curation">001E61</idno><idno type="wicri:Area/Main/Exploration">001D02</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Endocrine Gland Neoplasms (mortality)</term><term>Endocrine Gland Neoplasms (pathology)</term><term>Endocrine Gland Neoplasms (radionuclide imaging)</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Positron-Emission Tomography (methods)</term><term>Prospective Studies</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Receptors, Somatostatin (analysis)</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Indium Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Endocrine Gland Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Endocrine Gland Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Endocrine Gland Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The treatment of metastatic neuroendocrine tumors depends on the aggressiveness of the disease. We wanted to know whether (18)F-FDG PET and somatostatin receptor scintigraphy (SRS) can predict early disease progression and patient survival.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19443590</PMID><DateCreated><Year>2009</Year><Month>05</Month><Day>27</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.</ArticleTitle><Pagination><MedlinePgn>858-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.108.057505</ELocationID><Abstract><AbstractText Label="UNLABELLED">The treatment of metastatic neuroendocrine tumors depends on the aggressiveness of the disease. We wanted to know whether (18)F-FDG PET and somatostatin receptor scintigraphy (SRS) can predict early disease progression and patient survival.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We undertook a prospective study of patients with metastatic neuroendocrine tumor diagnosed between September 2003 and January 2006. After obtaining signed informed consent from the patients, we performed CT, SRS, and (18)F-FDG PET and reviewed histologic data. CT was repeated every 3 mo to assess the risk of early progressive disease (first 6 mo), progression-free survival, and overall survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-eight patients (mean age, 60 +/- 15 y) were included. Histologically, 4 patients had a high-grade and 34 a low-grade tumor. The results of (18)F-FDG PET and SRS were positive in 15 and 27 patients. The 2-y overall survival and progression-free survival were 73% and 45%; 16 patients had early progressive disease. Most (18)F-FDG PET-positive patients had early progressive disease (14/15, vs. 2/23 (18)F-FDG PET-negative patients), and most SRS-negative patients had early progressive disease (9/11, vs. 7/27 SRS-positive patients); (18)F-FDG PET gave excellent negative and positive predictive values of 91% and 93%; (18)F-FDG PET results correlated with progression-free survival (P < 0.001) and overall survival (P < 0.001) even when only low-grade tumors were considered. SRS was associated with progression-free survival (P < 0.001) and overall survival (P < 0.03). At multivariate analysis, only (18)F-FDG PET was predictive of progression-free survival.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">(18)F-FDG PET exhibits excellent predictive values for early tumor progression. (18)F-FDG PET and SRS results correlate with progression-free survival and overall survival even for histologically low-grade tumors. These explorations could be included in the initial work-up for metastatic neuroendocrine tumor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garin</LastName><ForeName>Etienne</ForeName><Initials>E</Initials><Affiliation>UPRESS EA 3890 and Department of Medical Imaging, Centre E. Marquis, Rennes, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Le Jeune</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Devillers</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cuggia</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>de Lajarte-Thirouard</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Bouriel</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Boucher</LastName><ForeName>Eveline</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Raoul</LastName><ForeName>Jean-Luc</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance>Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>138661-02-6</RegistryNumber><NameOfSubstance>pentetreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Endocrine Gland Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">mortality</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2009</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">jnumed.108.057505</ArticleId><ArticleId IdType="doi">10.2967/jnumed.108.057505</ArticleId><ArticleId IdType="pubmed">19443590</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19443590
|texte= Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19443590" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |